ASLAN Reports Acceptance Of Late Breaker Abstract On Eblasakimab Phase 2b Results As Oral Presentation And Three Additional Abstracts At 32nd European Academy Of Dermatology And Venereology Congress
Portfolio Pulse from Benzinga Newsdesk
ASLAN Pharmaceuticals has announced that its late breaker abstract on Eblasakimab Phase 2b results will be presented orally at the 32nd European Academy of Dermatology and Venereology Congress. Additionally, three more abstracts from ASLAN will be presented at the congress.
September 22, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ASLAN Pharmaceuticals' Eblasakimab Phase 2b results will be presented at a major dermatology congress, potentially increasing visibility and interest in the company's work.
The presentation of ASLAN's Eblasakimab Phase 2b results at a major congress increases the visibility of the company's work. This could potentially attract more interest from investors and partners, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100